FDA Taking Closer Look at Manufacturers’ Visual Testing Programs While USP Would Set New Limits for Particles
This article was originally published in The Gold Sheet
Executive Summary
FDA investigators are taking a closer look at parenteral manufacturers’ inspections for visible particles while a proposed USP standard would give more guidance – and much needed clarity – on establishing acceptable quality limits for particles and setting up visual inspection programs.